Ann: Phase IIB Clinical Trial of Schedule 3, page-11

I am also very optimistic, but find the constant delays are very frustrating. If they say results will be available early July, they should not still be pending on 18 July. The same as providing an update on the OTC after 30 June, when it was due by 30 June for the Arrotex Agreement. It is very concerning if they didn't know before 3 July that the deadline had been extended. The same thing announcing the extension of the PK studies deadline on the day they were due.

Under promise, over deliver is an old one but one BOD should think about. Stop promoting "near term" events and including dates if they are repeatedly not met. Instead of early July, why not just say July or "the coming months". It is very misleading and reflects poorly on management.

The only good news is unless they extend the deadlines again, there should be lots of news flow in the coming weeks, and hopefully positive.